DAFNA Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-267,402
| Closed | -$5.38M | – | 91 |
|
|
2026
Q1 | $5.38M | Sell |
267,402
-89,400
| -25% | -$1.44M | 1.22% | 23 |
|
|
2025
Q4 | $5.76M | Sell |
356,802
-65,929
| -16% | -$873K | 1.34% | 18 |
|
|
2025
Q3 | $5.15M | Sell |
422,731
-159,026
| -27% | -$2.2M | 1.27% | 17 |
|
|
2025
Q2 | $6.58M | Sell |
581,757
-170,602
| -23% | -$2.09M | 1.82% | 14 |
|
|
2025
Q1 | $8.68M | Sell |
752,359
-59,319
| -7% | -$605K | 2.46% | 13 |
|
|
2024
Q4 | $6.87M | Buy |
811,678
+88,000
| +12% | +$911K | 1.75% | 18 |
|
|
2024
Q3 | $8.38M | Sell |
723,678
-83,295
| -10% | -$1.05M | 1.98% | 17 |
|
|
2024
Q2 | $9.51M | Hold |
806,973
| – | – | 2.27% | 15 |
|
|
2024
Q1 | $9.57M | Buy |
806,973
+205,941
| +34% | +$2.75M | 2.18% | 15 |
|
|
2023
Q4 | $7.36M | Sell |
601,032
-4,500
| -0.7% | -$40.9K | 1.76% | 16 |
|
|
2023
Q3 | $5.83M | Sell |
605,532
-5,500
| -0.9% | -$56.2K | 1.81% | 16 |
|
|
2023
Q2 | $5.5M | Sell |
611,032
-5,000
| -0.8% | -$46.1K | 1.5% | 22 |
|
|
2023
Q1 | $4.84M | Hold |
616,032
| – | – | 1.45% | 24 |
|
|
2022
Q4 | $4.16M | Buy |
616,032
+360,719
| +141% | +$1.93M | 1.17% | 26 |
|
|
2022
Q3 | $3.71M | Sell |
255,313
-10,350
| -4% | -$145K | 1% | 33 |
|
|
2022
Q2 | $2.61M | Buy |
265,663
+75,000
| +39% | +$827K | 0.71% | 38 |
|
|
2022
Q1 | $2.81M | Hold |
190,663
| – | – | 0.73% | 38 |
|
|
2021
Q4 | $2.52M | Buy |
190,663
+1,500
| +0.8% | +$23.9K | 0.63% | 35 |
|
|
2021
Q3 | $3.3M | Buy |
189,163
+128,563
| +212% | +$2.61M | 0.88% | 28 |
|
|
2021
Q2 | $1.45M | Buy |
60,600
+2,000
| +3% | +$52.3K | 0.3% | 66 |
|
|
2021
Q1 | $1.5M | Buy |
+58,600
| New | +$1.54M | 0.36% | 64 |
|
|
2020
Q4 | – | Sell |
-208,054
| Closed | -$2.62M | – | 82 |
|
|
2020
Q3 | $2.62M | Sell |
208,054
-14,398
| -6% | -$180K | 0.85% | 33 |
|
|
2020
Q2 | $2.69M | Sell |
222,452
-12,500
| -5% | -$133K | 0.78% | 37 |
|
|
2020
Q1 | $1.8M | Buy |
234,952
+210,227
| +850% | +$2.84M | 0.75% | 35 |
|
|
2019
Q4 | $440K | Hold |
24,725
| – | – | 0.15% | 72 |
|
|
2019
Q3 | $287K | Hold |
24,725
| – | – | 0.11% | 79 |
|
|
2019
Q2 | $548K | Buy |
24,725
+1,500
| +6% | +$35.2K | 0.21% | 68 |
|
|
2019
Q1 | $665K | Buy |
23,225
+3,000
| +15% | +$65K | 0.29% | 61 |
|
|
2018
Q4 | $399K | Buy |
20,225
+2,500
| +14% | +$50.3K | 0.2% | 62 |
|
|
2018
Q3 | $392K | Buy |
+17,725
| New | +$240K | 0.16% | 64 |
|
Other funds holding KALV
DAFNA Capital Management's KALV Position: Q2 2026 in Review
DAFNA Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 267,402 shares — an estimated $5.38M sold.
DAFNA Capital Management first reported a position in KALV in Q3 2018 and held it in 30 quarters. The position peaked at $9.57M in Q1 2024. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- DAFNA Capital Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- DAFNA Capital Management sold 267,402 KalVista Pharmaceuticals shares in Q2 2026, an estimated $5.38M.
- DAFNA Capital Management first reported a position in KalVista Pharmaceuticals in Q3 2018 and held it in 30 quarters.
- DAFNA Capital Management's KalVista Pharmaceuticals position peaked at $9.57M in Q1 2024.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.